MaxCyte, Inc. Operating Income
MaxCyte, Inc. (MXCT) reported Operating Income of -$10.23 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-13
- MaxCyte, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$10.23M.
- MaxCyte, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$6.18M.
- MaxCyte, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$11.23M.
- MaxCyte, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$14.15M.
- MaxCyte, Inc. operating income (loss) for fiscal 2025 was -$51.90M.
- MaxCyte, Inc. operating income (loss) for fiscal 2024 was -$51.20M.
- MaxCyte, Inc. operating income (loss) for fiscal 2023 was -$48.30M.
- MaxCyte, Inc. operating income (loss) for fiscal 2022 was -$27.36M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$10.23M 10-Q · filed 2026-08-13 | -$16.42M 10-Q · filed 2026-08-13 | -$27.64M derived: sum of 3 quarters · filed 2026-08-13 | -$41.79M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$6.18M 10-Q · filed 2026-05-13 | -$17.41M derived: sum of 2 quarters · filed 2026-05-13 | -$31.56M derived: sum of 3 quarters · filed 2026-05-13 | -$45.79M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$11.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$25.38M derived: sum of 2 quarters · filed 2026-03-25 | -$39.60M derived: sum of 3 quarters · filed 2026-08-13 | -$51.90M 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | -$14.15M 10-Q · filed 2025-11-13 | -$28.38M derived: sum of 2 quarters · filed 2026-08-13 | -$40.67M 10-Q · filed 2025-11-13 | -$53.57M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$14.23M 10-Q · filed 2026-08-13 | -$26.52M 10-Q · filed 2026-08-13 | -$39.42M derived: sum of 3 quarters · filed 2026-08-13 | -$53.48M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | -$12.29M 10-Q · filed 2026-05-13 | -$25.20M derived: sum of 2 quarters · filed 2026-05-13 | -$39.25M derived: sum of 3 quarters · filed 2026-05-13 | -$51.22M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | -$12.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$26.95M derived: sum of 2 quarters · filed 2026-03-25 | -$38.92M derived: sum of 3 quarters · filed 2026-03-25 | -$51.20M 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | -$14.05M 10-Q · filed 2025-11-13 | -$26.02M derived: sum of 2 quarters · filed 2025-11-13 | -$38.30M 10-Q · filed 2025-11-13 | -$46.39M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$11.97M 10-Q · filed 2025-08-06 | -$24.24M 10-Q · filed 2025-08-06 | -$32.34M derived: sum of 3 quarters · filed 2025-08-06 | -$46.29M derived: sum of 4 quarters · filed 2025-08-06 | ||||
| 2024-03-31 | -$12.28M 10-Q · filed 2025-05-08 | -$20.37M derived: sum of 2 quarters · filed 2025-05-08 | -$34.32M derived: sum of 3 quarters · filed 2025-05-08 | -$47.40M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | -$8.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$22.05M derived: sum of 2 quarters · filed 2025-03-11 | -$35.12M derived: sum of 3 quarters · filed 2025-03-11 | -$48.30M 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | -$13.95M 10-Q · filed 2024-11-06 | -$13.95M 10-Q · filed 2023-11-08 | -$27.02M derived: sum of 2 quarters · filed 2024-11-06 | -$40.20M 10-Q · filed 2024-11-06 | -$40.20M 10-Q · filed 2023-11-08 | -$46.95M derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | -$13.07M 10-Q · filed 2024-08-06 | -$13.07M 10-Q · filed 2023-08-09 | -$26.25M 10-Q · filed 2024-08-06 | -$26.25M 10-Q · filed 2023-08-09 | -$33.00M derived: sum of 3 quarters · filed 2024-08-06 | -$40.71M derived: sum of 4 quarters · filed 2024-08-06 | ||
| 2023-03-31 | -$13.18M 10-Q · filed 2024-05-07 | -$13.18M 10-Q · filed 2023-05-10 | -$19.93M derived: sum of 2 quarters · filed 2024-05-07 | -$27.64M derived: sum of 3 quarters · filed 2024-05-07 | -$36.38M derived: sum of 4 quarters · filed 2024-05-07 | |||
| 2022-12-31 | -$6.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$14.46M derived: sum of 2 quarters · filed 2024-03-12 | -$23.20M derived: sum of 3 quarters · filed 2024-03-12 | -$27.36M 10-K · filed 2024-03-12 | -$27.36M 10-K · filed 2023-03-15 | |||
| 2022-09-30 | -$7.71M 10-Q · filed 2023-11-08 | -$16.45M derived: sum of 2 quarters · filed 2023-11-08 | -$20.61M 10-Q · filed 2023-11-08 | -$25.57M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | -$8.74M 10-Q · filed 2023-08-09 | -$12.90M 10-Q · filed 2023-08-09 | -$17.85M derived: sum of 3 quarters · filed 2023-08-09 | -$20.30M derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | -$4.16M 10-Q · filed 2023-05-10 | -$9.11M derived: sum of 2 quarters · filed 2023-05-10 | -$11.56M derived: sum of 3 quarters · filed 2023-05-10 | -$15.97M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | -$4.96M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$7.40M derived: sum of 2 quarters · filed 2023-03-15 | -$11.82M derived: sum of 3 quarters · filed 2023-03-15 | -$18.19M 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | -$2.44M 10-Q · filed 2022-11-09 | -$6.86M derived: sum of 2 quarters · filed 2022-11-09 | -$13.23M 10-Q · filed 2022-11-09 | -$15.61M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | -$4.42M 10-Q · filed 2022-08-10 | -$10.79M 10-Q · filed 2022-08-10 | -$13.17M derived: sum of 3 quarters · filed 2022-08-10 | -$16.01M derived: sum of 4 quarters · filed 2022-08-10 | ||||
| 2021-03-31 | -$6.37M 10-Q · filed 2022-05-09 | -$8.75M derived: sum of 2 quarters · filed 2022-05-09 | -$11.60M derived: sum of 3 quarters · filed 2022-05-09 | -$14.44M derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | -$2.38M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | -$5.22M derived: sum of 2 quarters · filed 2022-03-22 | -$8.07M derived: sum of 3 quarters · filed 2022-03-22 | -$11.06M 10-K · filed 2022-03-22 | ||||
| 2020-09-30 | -$2.84M 10-Q · filed 2021-11-10 | -$5.69M derived: sum of 2 quarters · filed 2021-11-10 | -$8.68M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | -$2.84M 10-Q · filed 2021-09-13 | -$5.83M 10-Q · filed 2021-09-13 | ||||||
| 2019-12-31 | -$12.42M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |